Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Avexa halts HIV drug trials

Avexa halts HIV drug trials

Gilead Sciences board authorizes $5 billion common stock repurchase program

Gilead Sciences board authorizes $5 billion common stock repurchase program

Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI

Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI

Updates on development of Truvada and TMC278

Updates on development of Truvada and TMC278

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences doses first patient in Quad Phase III clinical program

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA

Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Coformulation of rilpivirine and Truvada HIV drugs will achieve sales of more than $2 billion in 2018

Coformulation of rilpivirine and Truvada HIV drugs will achieve sales of more than $2 billion in 2018

R&D of HIV treatments at crossroads

R&D of HIV treatments at crossroads

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences to present Viread Phase III clinical trial data

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson announces financial results for the third quarter of 2009